BRIDGEWATER, N.J., Sept. 24, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of John P. Hamill as Senior Vice President & Chief Financial Officer effective today. Mr. Hamill brings over 25 years of global financial and administrative operational experience to Savient with a specialized background in pharmaceutical service industry. Mr. Hamill will be responsible for all financial and accounting functions of the Company and will report directly to Lou Ferrari, President and Chief Executive Officer of Savient. "John has a valuable combination of global financial, operational and public company experience which will be vital for us as we continue to execute on our strategic initiatives to drive growth opportunities for KRYSTEXXA® both in the U.S. and in markets around the world. He will be responsible for all aspects of our financial functions and for ensuring the Company meets its growth objectives in the most cost-effective manner through the implementation of financial and operational controls and the execution of the financial roadmap," stated Lou Ferrari. "I am happy and excited to be joining Savient at a time when there is such great growth potential and opportunity," said John Hamill. "I look forward to serving as a member of the Executive Committee and working with the entire Savient team in successfully growing the business in an efficient and strategic manner." Most recently, Mr. Hamill served as Chief Financial Officer of PharmaNet Development Group, Inc., a leading global supplier of drug development services, and its wholly owned subsidiary PharmaNet, Inc., where he directed financial and administrative operations. Prior to PharmaNet, Mr. Hamill held senior financial management positions of increasing responsibility and breadth at Omnicare Clinical Research and financial management positions at Rhone-Poulenc, Freedom Chemical Company, International Paper and Johnson & Johnson.